UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011182
Receipt number R000013073
Scientific Title Genomic examination and analysis for hereditary malignant tumors
Date of disclosure of the study information 2013/07/12
Last modified on 2021/07/18 10:05:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Genomic examination and analysis for hereditary malignant tumors

Acronym

Genomic examination and analysis for hereditary malignant tumors

Scientific Title

Genomic examination and analysis for hereditary malignant tumors

Scientific Title:Acronym

Genomic examination and analysis for hereditary malignant tumors

Region

Japan


Condition

Condition

herediraty breast and ovarian cancer, Cowden disease, Li-fraumeni syndrome, familial adenomatous polyposis, hereditary non-poliposis colon cancer

Classification by specialty

Gastrointestinal surgery Breast surgery Obstetrics and Gynecology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To establish programs of treatment and postoperative follow-up for hereditary cancer patients by accumulating the data of genomic mutations.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Efficacy of early detection program of hereditary cancers based on the results of genomic test

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Gene

Interventions/Control_1

Genetic test for BRCA1 and BRCA2 mutations

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients with suspected herediary malignand disease.
2. Relatives of patients with comfirmed hereditary malignant disease.
3. Healthy members of a pedigree of suspected hereditary malignant disease.

Key exclusion criteria

1. Not enough for the criteria of the disease.
2. Client who doesn't receive pre-counseling.
3. Client younger than 20 y.o.
4. Client without a consent.
5. Client who cannot pay for the genetic test.
6. Client unsuitable for genetic test based on the ethical issue.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasuhiro Tamaki

Organization

Osaka Medical Center for Cancer and Cardiovascular Diseases

Division name

Breast and Endocrine Surgery

Zip code


Address

1-3-3, Nakamichi, Higashinari-ku, Osaka, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Yasuhiro Tamaki

Organization

Osaka Medical Center for Cancer and Cardiovascular Diseases

Division name

Breast and Endocrine Surgery

Zip code


Address


TEL


Homepage URL


Email



Sponsor or person

Institute

Familial Cancer Study Group

Institute

Department

Personal name



Funding Source

Organization

Osaka Fundation for the prevention of cancer and cardiovascular diseases

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 07 Month 12 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2012 Year 09 Month 05 Day

Date of IRB


Anticipated trial start date

2013 Year 05 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 07 Month 12 Day

Last modified on

2021 Year 07 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013073


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name